Myriad Genetics, Inc. (MYGN) 주식 분석

회사 개요

Myriad Genetics, Inc. operates as a molecular diagnostics and precision medicine enterprise that develops and offers specialized molecular tests designed for oncology, women's health, and pharmacogenomics applications. Within the broader Healthcare sector, the company specifically functions in the Diagnostics & Research industry, where it focuses on leveraging DNA sequencing technology for hereditary cancer analysis through products like the MyRisk Hereditary Cancer test. The organization employs a workforce of 2,700 individuals and holds a market capitalization of $415.18 million, reflecting its current valuation in the public equity markets. With annual revenue totaling $557.00 million, the company's financial scale indicates a mid-sized market presence that has experienced a contraction in recent periods, suggesting a need for strategic adjustment to stabilize its market position against competitive pressures.

재무 건전성

The company reported trailing twelve-month revenue of $557.00 million, yet generated a net income of -$230,000,000, while reporting an EBITDA of -$111,900,000. The substantial gap between the positive revenue of $557.00 million and the significant net loss of $230,000,000 reveals a cost structure where operating expenses, including research and development and sales costs, heavily outweigh gross profits, resulting in a negative profit environment. Free cash flow stood at -$46,062,500, indicating that the company is currently consuming cash rather than generating liquidity, which limits its immediate financial flexibility for capital expenditures or acquisitions without external financing. Gross margin is reported at 68.1%, demonstrating high pricing power or low cost of goods sold typical for diagnostic testing, whereas the operating margin of -21.4% and profit margin of -41.3% highlight severe inefficiencies or high overhead costs eroding the bottom line. On the balance sheet, the company holds cash of $150.70 million against zero debt, resulting in a debt-to-equity ratio of 32.84 which technically appears high but is misleading in this specific context as it implies leverage on negative equity or specific accounting structures given the lack of actual debt obligations. The current ratio of 2.67 suggests a conservative liquidity position where current assets are more than double current liabilities, providing a buffer against short-term obligations despite the net loss. Return on Equity is -23.5% and Return on Assets is -7.6%, metrics that indicate management has not yet achieved profitability relative to the capital invested or assets deployed, reflecting the challenges in converting operations into shareholder value.

밸류에이션 평가

The valuation metrics show a trailing P/E ratio of N/A due to losses, while the forward P/E is 26.44, implying that the market is pricing in future earnings recovery rather than current profitability. The price-to-book ratio stands at 1.13, suggesting that the market values the company slightly above its net book value, which is unusual for a firm reporting negative earnings and indicates potential optimism regarding asset revaluation or intangible value. The price-to-sales ratio is 0.75, and the EV/EBITDA is -2.36, providing alternative perspectives that the company is trading at less than one dollar of sales per dollar of revenue, while the negative EV/EBITDA reflects the inability to generate earnings before interest and taxes in the current period. The stock's 52-week trading range spans from a low of $3.76 to a high of $8.59, providing a context for price volatility within the last year. Without a specific current price provided in the facts, the valuation relative to the 52-week high and low cannot be calculated as a percentage, but the range defines the historical volatility floor and ceiling for the security. The beta of 1.64 indicates that the stock is significantly more volatile than the broader market, moving with an amplified intensity that reflects the high risk associated with biotechnology and diagnostic sectors.

Growth & Income

Revenue growth year-over-year is recorded at -20.8%, while earnings growth is listed as N/A due to the absence of prior year positive earnings for comparison. The decline in revenue suggests a contraction in demand or loss of market share, and since earnings are already negative, the concept of earnings growing faster or slower than revenue is currently inapplicable as the firm is operating at a loss. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as the dividend yield is N/A and the payout ratio is 0.0%. This 0.0% payout ratio indicates that the company retains all earnings or cash reserves to fund operations and research, though with current net losses, it is burning cash rather than reinvesting profits. The overall growth and income profile is characterized by negative revenue momentum and a lack of current profitability, with no income generated for shareholders through dividends, requiring a reliance on future operational turnaround to restore positive cash flow and earnings.